Abstract

Purpose
In recent years, perfluorochemicals (abbreviated as PFCS) have been further refined and have been suggested as artificial blood substitutes. Perftoran, an available PFC in Russia, is a mixture of perfluorodecalin and perfluor-n-metylcyclohexyl-piperidine. This study was designed to determine the effectiveness of perftoran in vivo. Methods: This study was based on an unanesthetized hemorrhagic rat model (30% blood volume loss). The 5 groups studied were as follows: 1. control - no resuscitation fluid in room air 2. normal saline solution - 2.5 times shed blood volume in room air, 3. normal saline solution - 2.5 times shed blood volume in an oxygen supplement, 4. perftoran (PFC: artificial blood substitute) - 1 times shed blood volume in room air, 5. perftoran (PFC: artificial blood substitute) - 1 times shed blood volume in an oxygen supplement. Arterial blood gas, electrolyte, complete blood count were measured parameters. The data were analyzed statistically for differences between the groups (kruskall-wallis analysis). Results: After the infusion of 40% perftoran, the volume of PaO2 measured 10~30 mmHg higher than that of either the control or the saline resuscitation groups. The PaCO2, pH and lactate showed no significant changes after the infusion of 40% perftoran. Conclusion: Perftoran is available for transfusion in the experimental hemorrhagic shock rat model. Further studies are encouraged to investigate its usefulness as an artificial blood substitutesfor the future.

• Keywords: Artificial blood substitutes, Perfluorocarbon, Perftoran